TY - JOUR
T1 - Inhibitory Effect of Atmospheric Pressure Plasma on GH3 Pituitary Adenoma Cell Line and Primary Pituitary Tumor Cells From Patients
AU - Fang, Qiuyue
AU - Liu, Yixiao
AU - Xing, Yanan
AU - Zhang, Xi
AU - Liu, Yuqing
AU - Liu, Yuxuan
AU - Sun, Zhiyan
AU - Guo, Yuqi
AU - Liu, Yulou
AU - He, Gaosheng
AU - Xu, Lixin
AU - Xu, Xiaojin
AU - Ouyang, Jiting
AU - Li, Chuzhong
AU - Yan, Xu
N1 - Publisher Copyright:
© 2017 IEEE.
PY - 2025
Y1 - 2025
N2 - Although atmospheric pressure plasma (APP) treatment has exhibited promising antitumor efficacy across various cancer types, no studies have analyzed the effects of APP on pituitary adenoma. In this study, APP generation and treatment conditions were optimized and investigated. Four pituitary tumor cell lines (GH3, AtT-20, GT1-1, and MMQ) were used to assess the inhibitory effect of APP treatment and were compared with two glioblastoma (GBM) cell lines (U87MG and LN229) and a neuronal cell line (SH-SY5Y). Results showed that the APP treatment has a better inhibitory effect on pituitary tumor cells with minimal neurotoxicity. The best inhibitory effect was observed in GH3, which had an IC50 value of only 32.33 s. APP treatment elevated both intra-and extracellular reactive oxygen/nitrogen species (ROS/RNS) in GH3 cells, which induced significantly GH3 cell apoptosis. Non-invasive Micro-test Technology (NMT) experiment revealed substantial Ca2+ influx following APP treatment in GH3 cells. Moreover, validation on primary pituitary tumor cells from patients corroborated these findings. Overall, our results highlight that APP treatment exerts substantial antitumor effects on pituitary adenoma cells compared to GBM cell lines, suggesting its potential as a complementary therapy in clinical neurosurgical treatment of pituitary adenoma.
AB - Although atmospheric pressure plasma (APP) treatment has exhibited promising antitumor efficacy across various cancer types, no studies have analyzed the effects of APP on pituitary adenoma. In this study, APP generation and treatment conditions were optimized and investigated. Four pituitary tumor cell lines (GH3, AtT-20, GT1-1, and MMQ) were used to assess the inhibitory effect of APP treatment and were compared with two glioblastoma (GBM) cell lines (U87MG and LN229) and a neuronal cell line (SH-SY5Y). Results showed that the APP treatment has a better inhibitory effect on pituitary tumor cells with minimal neurotoxicity. The best inhibitory effect was observed in GH3, which had an IC50 value of only 32.33 s. APP treatment elevated both intra-and extracellular reactive oxygen/nitrogen species (ROS/RNS) in GH3 cells, which induced significantly GH3 cell apoptosis. Non-invasive Micro-test Technology (NMT) experiment revealed substantial Ca2+ influx following APP treatment in GH3 cells. Moreover, validation on primary pituitary tumor cells from patients corroborated these findings. Overall, our results highlight that APP treatment exerts substantial antitumor effects on pituitary adenoma cells compared to GBM cell lines, suggesting its potential as a complementary therapy in clinical neurosurgical treatment of pituitary adenoma.
KW - Atmospheric pressure plasma
KW - Inhibitory effect
KW - Pituitary adenoma
KW - Plasma medicine
KW - Primary pituitary tumor cells
KW - Reactive species
UR - http://www.scopus.com/inward/record.url?scp=105001204895&partnerID=8YFLogxK
U2 - 10.1109/TRPMS.2025.3552789
DO - 10.1109/TRPMS.2025.3552789
M3 - Article
AN - SCOPUS:105001204895
SN - 2469-7311
JO - IEEE Transactions on Radiation and Plasma Medical Sciences
JF - IEEE Transactions on Radiation and Plasma Medical Sciences
ER -